Expression of microRNAs in the Urine of Patients With Bladder Cancer

Wang, Gang; Chan, Eddie Shu‐Yin; Kwan, Bonnie Ching‐Ha; Li, Philip Kam-Tao; Yip, Sze Fai; Szeto, Cheuk‐Chun; Ng, Chi‐Fai

doi:10.1016/j.clgc.2012.01.001

Cited by 134 publications

(112 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It was also shown that the levels of these miRNAs were altered after surgery. The postsurgical levels of miR-200a, miR-200b, miR-200c, miR-141, miR-429, miR-205, miR-192 and miR-146a increased significantly, whereas the level of miR-155 remained similar (101). Taken together, these results suggest that bladder cancer is the direct cause of depressed urinary miRNA levels, but the mechanism of this suppression is unknown.…”

Section: Urine Mirna Detection In Urological Cancersupporting

confidence: 58%

“…These characteristics indicate that urinary miRNAs are a potential biomarker for bladder cancer and UC screening. It has been reported that patients with bladder cancer have lower expression of miR-200 family members (miR-200a, miR-200b and miR-200c), miR-192 and miR-155 in the urinary sediment, and higher expression of miR-155 in the urinary supernatant (101). It was also shown that the levels of these miRNAs were altered after surgery.…”

Section: Urine Mirna Detection In Urological Cancermentioning

confidence: 70%

“…In addition, miRNAs have been reported to be stable in the urine and also show high specificity and sensitivity (95,(101)(102)(103). These characteristics indicate that urinary miRNAs are a potential biomarker for bladder cancer and UC screening.…”

Section: Urine Mirna Detection In Urological Cancermentioning

confidence: 89%

See 2 more Smart Citations

microRNA detection in feces, sputum, pleural effusion and urine: Novel tools for cancer screening (Review)

et al. 2013

View full text Add to dashboard Cite

Abstract. microRNAs (miRNAs) are short non-coding RNA sequences that play important roles in the regulation of gene expression. They have significant regulatory functions in basic cellular processes, including differentiation, proliferation and apoptosis. miRNAs are differentially expressed in tumors, compared with normal tissues. Importantly, miRNAs are also stable and abundantly present in body fluids and feces. The high reproducibility, sensitivity and specificity of miRNAs in body fluids and feces enable miRNAs to be used as potential molecular markers for cancer screening. An increasingly large number of research studies have reported the role of miRNAs in this field. In the present review, we focused mainly on the application of detecting miRNAs in stool, sputum, pleural effusion and urine, to detect colon, lung and urological cancers, highlighting the role of miRNAs in early diagnosis and prognosis. IntroductionCancer is currently the most lethal human disease. Lung and colorectal cancers are the first and third most common types of cancers and the leading causes of cancer-related mortality worldwide (1). Bladder cancer, a urological cancer, is the second most common malignancy that involves the urinary system, and the clinical outcome is often poor once the tumor becomes invasive (2). Although much progress has been made in the prevention, early diagnosis and treatment of cancer, survival rates are still not optimistic, indicating that a more powerful method to detect cancer in the early stages is needed. Early detection of cancer has been reported to greatly improve both the survival rate and prognosis, suggesting that the key to oncotherapy may lie in early diagnosis (3-7). Thus, developing a method for the early detection of cancer is both important and necessary. Ideally, an early detection method would have high sensitivity, specificity and repeatability, and would be safe, affordable and acceptable to the patient as well.Traditional methods, such as colonoscopy (8), bronchoscopy (9) and cystoscopy (10), are used to detect colon cancer, non-small cell lung cancer (NSCLC) and bladder cancer, respectively. These methods have greatly benefited many individuals in the past and they are still used to diagnose cancer. However, their use has been hampered by their invasive nature, the manpower resources they require, their high cost and the discomfort they cause patients (11-13).Biological screening methods, including the fecal occult blood test (FOBT) for colon cancer; sputum cytology for NSCLC (14); and the bladder tumor antigen (BTA test), BTA stat test, nuclear matrix protein 22 (NMP22), and urinary cytology for bladder cancer, have also been applied in recent years. However, these methods each have a significant sensitivity (15,16) or specificity (13), but not both.As previously mentioned, these methods have drawbacks that prevent their wide application.

show abstract

Section: Urine Mirna Detection In Urological Cancersupporting

confidence: 58%

Section: Urine Mirna Detection In Urological Cancermentioning

confidence: 70%

See 1 more Smart Citation

microRNA detection in feces, sputum, pleural effusion and urine: Novel tools for cancer screening (Review)

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Previous studies found that miR-192 is significantly increased in many types of cancer (39)(40)(41), but decreased in many others (42,43). Studies have also shown that p53-mediated upregulation of miR-192 prevents EMT in hepatocellular carcinoma through repression of the transcription factor ZEB2 (44).…”

Section: Discussionmentioning

confidence: 99%

Plasma miR-122 and miR-192 as potential novel biomarkers for the early detection of distant metastasis of gastric cancer

Chen

Zhang

et al. 2014

Oncology Reports

View full text Add to dashboard Cite

Abstract. The aim of the present study was to ascertain whether plasma levels of specific microRNAs (miRNAs) are associated with distant metastasis (DM) in gastric cancer (GC). miRNA profiling was performed on 12 pairs of samples of gastric cancer with distant metastasis (GC/DM) and gastric cancer with no distant metastasis (GC/NDM); 14 differentially expressed miRNAs were identified for further inspection. Validation of these 14 miRNAs using quantitative reverse transcription PCR (qRT-PCR) on an independent validation set identified 2 differentially expressed miRNAs (miR-122 and miR-192). Further validation of these two candidate miRNAs was conducted in a disease control set, a self-paired plasma set and finally in gastric cell lines in vitro. The results revealed that when compared with GC/NDM and healthy controls (HCs), plasma levels of miR-122 were significantly lower and plasma levels of miR-192 were significantly higher in GC/DM samples (both P<0.01). The plasma miR-122 level was again lower and the plasma miR-192-level was again higher in patients with GC/DM than in patients with benign gastric ulcer (BGC) and chronic gastritis (CG) (P<0.01). Compared to the level in patients with pre-distant metastases, miR-122 was significantly decreased while miR-192 was markedly elevated in patients with post-distant metastases (P<0.01). In CTC105 and CTC141 cells, miR-122 levels were moderately lower and miR-192 levels were markedly higher when compared to the levels in the GES-1 cells. ROC analyses showed that the AUC for plasma miR-122 was 0.808 (95% CI, 0.712-0.905; P<0.01), and the AUC for plasma miR-192 was 0.732 (95% CI, 0.623-0.841; P<0.01) for distinguishing GC/ DM from GC/NDM. High expression of miR-122 in plasma independently contributed to a more favorable prognosis for GC (hazard ratio, 0.262; 95% CI, 0.164-0.816; P= 0.038; Cox regression analysis), whereas the miR-192 level was not associated with the overall survival time. Our results demonstrated that assessment of decreased circulating miR-122 and elevated circulating miR-192 levels has the potential to improve early detection of DM in GC. Higher plasma levels of miR-122 in GC may indicate a favorable prognosis.

show abstract

“…Numerous studies investigated miRNA profiling signature of bladder carcinomas distinguishing different classes, stages of progression and outcomes (Wiklund et al, 2011;Dip et al, 2012;Wang et al, 2012;Tran et al, 2013). For instance, Neely et al (2010) noted that a miR-21:miR-205 expression ratio can be used to distinguish invasive and non-invasive bladder tumors.…”

Section: Mir-205 In Other Cancersmentioning

confidence: 99%